A study using the meningococcal disease diagnostic developed at the laboratories in the Royal Victoria Hospital, Belfast, has recently been published in The Lancet Infectious Diseases. The paper concludes that the meningococcal LAMP assay is straightforward enough to use in any hospital with basic laboratory facilities and provides diagnostically accurate and clinically useful results.
Read more ...Belfast Health and Social Caree Trust licensee HiberGene Diagnostics Ltd has raised €2m. The company will use this round of funding to support the commercialisation of its first two rapid molecular tests for Meningococcal Meningitis and Group B Streptococcus, which were developed at the Royal Victoria Hospital in Belfast and which it has licenced from Belfast HSC Trust.
Read more ...
Belfast Health and Social Care Trust has licensed its rapid molecular diagnostic for Group B streptococcus to HiberGene Diagnostics Ltd. The Group B streptococcus assay is 100% sensitive and 93% specific when compared to direct culture.
Read more ...The patent application filed by Belfast Health and Social Care Trust to protect its rapid meningitis diagnostic has been granted in the USA. Granted patent US8465927 – Detection of Neisseria meningitidis by loop mediated isothermal amplification – is licensed exclusively to HiberGene Diagnostics Ltd, a rapid molecular diagnostics company, for its meningococcal diagnostic.
Read more ...
Belfast Trust licenses patent to HiberGene Diagnostics HSC Innovations is pleased to announce that Belfast Health and Social Care Trust has licensed its novel rapid meningitis diagnostic test to HiberGene Diagnostics Ltd, a start-up client company of NovaUCD, the Innovation and Technology Transfer Centre, Dublin, Ireland. Novel Rapid Meningitis Diagnostic Test Moves Closer To
Read more ...